NM_001034853.2(RPGR):c.179G>T (p.Gly60Val) is a missense variant that replaces glycine with valine at amino acid 60. This variant is absent from hemizygous individuals in gnomAD v4.1.0 (PM2_supporting). At least one proband harboring this variant exhibits a phenotype including family history consistent with X-linked inheritance (2 pts) with delayed or milder phenotype in females (1 pt), visual field reduction (0.5 pts), central vision problem (0.5 pts) since 6 years of age (1 pt), poor night vision (0.5 pts), pigmentary retinopathy (0.5 pts), and nondetectable electroretinogram responses, which together are specific for RPGR-related retinopathy (6 points, PMID: 9855162, PP4). This variant has been reported in other publications, however, the ability to conclude that the probands described are unrelated was not successful (PMIDs: 28559085, 10937588, 34985506, 9399904, 9855162). The variant has been reported to segregate with retinal dystrophy through at least 4 meioses from at least 1 family (PP1_moderate; PMID: [9855162]). The computational predictor REVEL gives a score of 0.98, which is above the ClinGen X-linked IRD VCEP threshold of ≥ 0.932 and predicts a damaging effect on RPGR function (PP3_strong). The computational splicing predictor SpliceAI gives a delta score of 0.19 for acceptor loss, which is below the ClinGen X-linked IRD VCEP threshold of >0.2 and does not predict that the variant disrupts RPGR splicing. Exogenously expressed RPGR harboring the variant exhibits reduced interaction with RPGRIP1 in a yeast-2-hybrid experiment (PMID: 23213406, 23213406, PS3_supporting). In summary, this variant is classified as likely pathogenic for RPGR-related retinopathy based on the ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPGR Version 1.0.0; PM2_supporting, PP1_moderate, PP3_strong, PS3_supporting, and PP4. (date of approval 05/16/2025).